it depends which vaccine you are testing and whether there are WHO or other institutional recommendations for that vaccine. Usually the non inferiority with 10% margin has to be evaluated for new vaccines as compared to licensed ones (i.e. D,T, pertussis, Hep B , Hib). The endpoint is the proprotion of responders/seroconversion not the GMTs/GMCs